RxDoctor Payments Data

Chad McCain, DO

Family Medicine · Hillsborough, NCNPI 1467800045

Payments from drug & device makers

$742in general payments, 2019–2025

Across 10 payments — averaging $74.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$204
  • Blueprint Medicines Corporation$109
  • Bristol Myers Squibb$106
  • AbbVie$99
  • GSK$95
  • Boehringer Ingelheim$88
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$742100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$742 in reported general payments places this provider in the 65th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$35,052
Medicare patients
119
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$96,799
JardianceEmpagliflozin39$38,922
TrulicityDulaglutide23$22,325
RybelsusSemaglutide11$13,613
Spiriva RespimatTiotropium Bromide15$7,486
Atorvastatin Calcium156$1,978
Losartan Potassium188$1,729
Metformin Hcl ErMetformin Hcl88$1,559
Sucralfate12$1,456
Levothyroxine Sodium90$1,387
Omeprazole81$1,250
Metoprolol Succinate65$1,230
Albuterol Sulfate HfaAlbuterol Sulfate53$1,222
Tamsulosin Hcl45$1,161
Amlodipine Besylate187$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$14$110,41377 claims
Boehringer IngelheimJardiance, Spiriva Respimat$88$46,40954 claims
Lilly USA, LLCTrulicity$12$22,32523 claims
AbbVieSynthroid$99$40214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Hillsborough

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →